AI tailwind real, but Q1 execution soft; TMT bottoming claimed
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Delivered Q1 numbers match reported. Guided 19% historical growth; achieved 20% headline (9% cc). Margins expanding. TMT recovery guidance unproven. No FY27 guidance given.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong margin expansion and AI tailwind are real, but Q1 execution was mixed: TMT down 22% YoY, PAT fell 37.6% QoQ, and constant-currency growth (9%) reveals FX flatter. Mgmt candid about execution gaps and reorganizing under new CCO. Believe long-term AI opportunity is substantial, but need proof of TMT recovery and license revenue scale before upgrading.
₹912.5 Cr
Revenue · +20% YoY₹72.3 Cr
Reported PAT · +92% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue ₹912.5 Cr, up 20% YoY
METDelivered ₹912.5 Cr confirmed; 20% headline matches. Constant currency only 9%.
Net income grew 92% to ₹72 Cr
METDelivered ₹72.3 Cr, NPM 7.9%. QoQ PAT declined 37.6%.
Adjusted EBITDA grew 35% YoY, margin 17% (+189 bps)
OVERSTATEDConfirmed. But 273 bps FX benefit; merit/headcount added 244 bps drag.
TMT bottoming out, healthy sequential growth expected Q2
MISSTMT down 22% YoY this quarter. Visibility claimed but not yet proven.
Gross margin 46%, up 29 bps YoY
METDelivered 46% confirmed. FX-flattered; operational leverage still modest.
License revenue growing, targeting 60% outcome/outcome/license
PartialCurrently 3% and 42% respectively. No timeline specificity for 60% target.
Earnings quality
What changed since the last call
TMT outlook: deteriorated then reset
DowngradePrior: Expected recovery. Actual: Down 22% YoY in Q1. New: Mgmt claims bottoming, expects sequential recovery Q2. Unproven.
Reorganized go-to-market
NewNew Chief Commercial Officer (Matt) appointed to lead three-pillar strategy (AIT, AIF, AIW). Reflects execution urgency. Not baked into Q1 results yet.
License revenue positioning
NewPrior: Outcome/license goal was 60% in 2–3 years. Now: 42% of mix, targeting 60% in 'next few quarters.' More aggressive timeline, but definition still vague.
FY27 guidance withheld
WithdrawnNo formal revenue/margin targets given. Prior calls included growth and margin outlook. Mgmt cites market fluidity and execution uncertainty.
R&D investment pace raised
UpgradeWill increase to 10% of revenue, backed by gross margin expansion. Q1 R&D was ₹61 Cr (+31% YoY). Prior: disciplined but unspecified target.
The Q&A
Analysts pressed hard on TMT decline, visibility, and deal velocity. Mgmt deflected client-specific blame, attributed to tech sector capex/opex reallocation. On volatility, acknowledged but reframed as market shift opportunity. Q&A showed skepticism on FY27 growth trajectory; responses defensive but candid on execution gaps.
TMT vertical decline — Gaurav Rateria, Morgan Stanley
PartialNew deals from existing clients; significant pipeline already in hand. TMT bottoming; sequential growth expected Q2. Deal sizes increasing overall, but Fractal has to prove execution.
Cogentiq pipeline nature — Gaurav Rateria, Morgan Stanley
AnsweredMostly product-led. Cogentiq for underwriting, e-commerce, supply chain seeing traction. Built for enterprise trust (control, ontology, security). Few clients signed. Will become significant revenue engine.
Business volatility and consistency — Gaurav Rateria, Morgan Stanley
PartialDemand shape shifting rapidly. Old ad hoc work vanishing. Large AI deals coming through, but volume compression also real. Larger RFPs incoming; Fractal better positioned as it grows. Deal velocity to improve with new go-to-market.
TMT vertical drivers — Aditi Patil, ICICI Securities
DodgedNo new dramatic client loss called out. Mgmt won't detail client issues going forward. TMT did worse than expected; worst behind us. Expects sequential improvement Q2.
Cogentiq revenue and scale — Aditi Patil, ICICI Securities
PartialLicense revenue is 3% of total. Cogentiq pipeline strong; deal sizes smaller than services. Will report Cogentiq revenue separately next quarter. Expected to grow materially.
FY27 growth trajectory — Pritesh Thakkar, PL Capital
PartialExcluding TMT, growth is 35%. With TMT recovery, overall growth will improve. Hiring new leaders (Chief Practice Officer BFSI, new Europe head). Growth opportunities across all verticals. Execution critical.
Industry growth outlook — Moez Chandani, Ambit
AnsweredAI demand enormous, growing fast, taking share from consulting/research/ads. Total TAM increasing. Tech budget share going from 4.5% to 6% of revenue. AI addressable market dramatically expanding. Execution challenge, not demand shortage.
TMT decline root cause — Moez Chandani, Ambit
PartialBig tech capex doubled; opex pressure result. Allocating more to capex, less to opex. Some TMT sector shift playing out, but Fractal taking accountability for execution.
Client concentration and large-deal trend — Om Kavadi, Avendus Spark
AnsweredYes, one TMT client slipped below ₹20M. Best viewed year-over-year, not TTM. By year-end, will assess if count went 6→7 or held at 6.
R&D and outcome mix targets — Om Kavadi, Avendus Spark
AnsweredCurrently 42% outcome/license, targeting 60% in next few quarters. R&D to rise to 10% of revenue, only on back of gross margin expansion. R&D to revenue conversion to accelerate. Work backwards from revenue.
Execution priorities — Sucrit Patil, Eyesight Fintrade
AnsweredThree pillars: AI-led business transformation, AI Foundations, AI Workforce transformation. Hiring leaders across verticals. Talent upgrade to meet shifting demand shape. Partnerships critical (Databricks, OpenAI, Anthropic).
Financial risks and balance sheet — Sucrit Patil, Eyesight Fintrade
AnsweredBalance sheet solid. DSO 71 days, cash conversion 70% of EBITDA. ROCE ~13%. Hedge forex only on cash flow. Data security top priority (Black Kite highest rating). No major financial risks flagged.
Fractal Alpha profitability trajectory — Anish Khanal, Eternalis Capital
AnsweredLoss increase from investments in Analytics Vidhya products (EdTech, iqigai reclassification). Asper ARR up 59% but revenue lag due to contract/recognition timing. Expect profitability recovery as scale increases.
EBITDA margin trajectory — Anish Khanal, Eternalis Capital
PartialQ1 is seasonally weak for profitability. YoY comparison more relevant: 15% to 17% is positive trend. Margins improving sequentially. As TMT recovers, margin headwinds ease. Long-term trajectory positive.
Guidance
TMT vertical to show healthy sequential growth Q2 FY27
MediumSignificant pipeline claimed from existing clients. But Q1 was -22% YoY; evidence only in mgmt words, not data.
Overall growth excluding TMT is 37% YoY; implies 60%+ growth if TMT recovers
HighDelivered result validates ex-TMT growth. Proof of concept exists, but TMT recovery timing uncertain.
Gross margins to continue expanding, driven by AI mix shift and scale
MediumQ1 showed +29 bps YoY, but FX accounted for 273 bps; operational gain modest. Dependent on deal mix and cost absorption.
Adjusted EBITDA margins to improve as SG&A leverage and gross margin expand
MediumAchieved 189 bps improvement Q1 YoY. Q1 seasonally weak; Q2+ comparisons more relevant. Sustained leverage requires consistent revenue growth.
Risks the call surfaced
Industry/Vertical concentration
HighTMT down 22% YoY, dragging overall growth from 37% ex-TMT to 20% headline. Tech capex/opex shift durably changing demand. Recovery timing uncertain.
FX headwind reversal
MediumWeaker rupee added 273 bps to gross margin and ~11pp to revenue growth headline. If rupee strengthens, both margins and growth rates will compress.
License revenue execution
MediumLicense revenue only 3% of total; target is 60% over 'next few quarters' (vague). Deal sizes smaller than services. Risk of product-market fit challenges or longer sales cycles.
Execution and organizational change
MediumNew Chief Commercial Officer (Matt) hired; reorganized under three pillars (AIT, AIF, AIW). Srikanth acknowledges execution challenges and need to move faster. Restructuring can cause short-term friction.
Associate/JV losses
LowQure.ai share of loss ₹23 Cr (up from ₹22 Cr YoY). Fractal Alpha segment loss ₹14 Cr (up from ₹4 Cr). Both temporary but material to net income.
Management
Score 7/10. Candid on Q1 underperformance. Acknowledged execution challenges and need for reorganization. Detailed on margin drivers (FX, merit, headcount). Declined to discuss client-specific TMT issues going forward (accountability shift). Transparent on segment losses and timing lags. Met headline revenue target (20% YoY). Delivered margin expansion (189 bps EBITDA YoY). But constant-currency growth 9% (below 19% historical), and QoQ PAT -37.6% shows momentum slowing. TMT recovery not yet in data. Track record: honest on near-term, confident on long-term.
1 · Q2 FY27 (Jul–Sep 2026)
TMT vertical recovery with sequential growth; large healthcare AI deal revenue recognition
2 · Q2-Q3 FY27
Asper ARR to revenue lag closes; Analytics Vidhya integration operating leverage materializes
3 · FY27 (ongoing)
New CCO-led go-to-market (AIT, AIF, AIW vectors) to accelerate AI-led transformation deal wins
Believe long-term AI opportunity is substantial, but need proof of TMT recovery and license revenue scale before upgrading.
Fractal's 20% Revenue Growth Is a 9% Constant-Currency Story
Headline growth of 20% masks a 9% constant-currency reality—less than half Fractal's historical 19% run rate. Strip out the FX tailwind, and Q1 reveals real execution challenges: TMT down 22% YoY and unproven bottoming, PAT momentum negative quarter-on-quarter, license revenue still trivial at 3%, and no FY27 guidance given. The market's -8.67% day-1 reaction was justified.
Where the growth really sits
Fractal reported Q1 revenue of ₹912.5 Crore, up 20% year-over-year. But that headline number carries a 11-percentage-point FX tailwind from a weaker rupee. Constant-currency growth—the operative measure—was only 9%. For a business that has historically guided around 19% revenue growth, 9% organic represents a material deceleration. This is the real story of the quarter.
+20%
Reported, includes FX boost
+9%
Organic; less than half historical rate
~11pp
Pure currency, not operations
The currency effect extended to margins. Gross margin improved 29 basis points to 46% year-over-year, but 273 basis points of that gain came from FX. This means merit increases and headcount additions—necessary to support future growth—subtracted 244 basis points from the margin line. On a currency-neutral basis, operational margin deteriorated. Management is simultaneously claiming 'margin expansion' and restructuring with a new Chief Commercial Officer. Without the rupee tailwind, the quarter's operational performance is notably softer than the headline suggests.
What management claimed vs. what the numbers show
Revenue ₹912.5 Cr, up 20% YoY
True at 20% reported, but growth is 20% only because of FX. Constant-currency is 9%—a step down from historical 19%. The operative growth is disappointing.
Supported on headline only
Net income up 92% to ₹72.3 Cr
+92% YoY looks strong. But quarter-on-quarter PAT fell 37.6%—a steep momentum deterioration. Mgmt cited seasonality (variable pay payout), but the trend is material and warrants close watch.
Supported YoY, momentum broken
Adjusted EBITDA margin 17%, up 189 bps YoY
FX accounted for 273 bps of the 189 bps net improvement. Merit and headcount additions subtracted 244 bps. Operative leverage was negligible to negative—the margin gain is mostly currency-driven.
Overstated
TMT vertical bottoming; healthy sequential growth expected Q2
TMT fell 22% YoY in Q1. Mgmt claims 'significant pipeline' and 'sequential recovery' ahead, but provided no numbers. Visibility is opaque; the claim rests on management words, not data.
Contradicted
License revenues to grow beyond 3%; targeting 60% outcome/output/license mix over next few quarters
License revenue is 3% of total; current outcome/output/license mix is 42%. The 60% target is aggressive, but timeline shifted from '2–3 years' (prior call) to 'next few quarters'—tightened but still vague. Product-market fit unproven.
Partial
What changed on this call
New Chief Commercial Officer (Matt) appointed; go-to-market restructured into three pillars (AI-led Transformation, AI Foundations, AI Workforce)
License-revenue timeline accelerated: 60% outcome/output/license target moved from '2–3 years' (prior call) to 'next few quarters'
FY27 full-year guidance withheld—unusual for Fractal; mgmt cited market fluidity and execution uncertainty
R&D investment rising to 10% of revenue, backed by gross-margin expansion and cost absorption
Org restructuring signals execution urgency; mgmt admits it moved too slowly and must accelerate to capture AI opportunity
The withholding of FY27 guidance is the most telling shift. Fractal has historically provided forward-looking revenue and margin targets; this call omitted them entirely. Management attributed this to 'market fluidity' and 'execution uncertainty,' but the reality is starker: without the FX tailwind and facing TMT headwinds, near-term visibility is constrained. The new go-to-market structure is operationally sound—clearer accountability, three distinct AI value vectors—but it's not yet embedded in the numbers. Q1 is the last quarter under the old structure; execution under the new one starts now.
How the market read it—and why the skepticism is warranted
Fractal's stock fell 8.67% on day 1 following the results announcement, with 57.8% of volume in delivery—a decisive institutional rejection. The stock now trades ₹809.3, down 27.42% from its all-time high, below both its 20-day and 50-day moving averages, and in a clear downtrend. Ownership data shows FII still hold 40.48%, but the trajectory is likely downward as institutions reduce exposure to an execution-dependent restructuring.
₹809.3
vs ATH ₹1115; -27.4% from peak
-8.67%
Heavy delivery (57.8%); institutional exit signal
Below SMA20/SMA50
Below ₹858 / ₹920 respectively
45
Neutral; room for further decline
The 27% drawdown from ATH is steep but justified by accumulated concerns, not Q1 alone: constant-currency growth missed historical guidance (9% vs. 19%), TMT's 22% YoY collapse is unproven bottoming, PAT momentum is negative quarter-on-quarter, license-revenue strategy remains speculative (3% of revenue), and the withholding of FY27 guidance signals management uncertainty on near-term delivery. The stock is pricing in a re-rating from 'growth at scale' to 'restructuring execution play.' That's fair.
The bull-bear ledger
AI opportunity is structural and expanding. Fractal ex-TMT grew 37% YoY—proof it can capture the shift when execution is clean.
Customer health strong: NRR 117%, top-10 concentration de-risked to 51.8%, Net Promoter Score 77. Land-and-expand is working.
Strategic partnerships (Databricks, OpenAI, Anthropic) widening moat. 42 joint engagements via partners; 5 of Q1's largest deals partner-sourced.
H2 seasonally strong with visible catalysts: Qure.ai revenue +160% YoY, backlog ₹100+ Cr (vs ₹20 Cr prior year); Asper ARR +59% YoY.
Constant-currency growth only 9%, vs. historical 19%. FX flatter reveals real deceleration and limits the growth narrative.
TMT vertical down 22% YoY with unproven recovery. If tech capex/opex shift is durable, this headwind persists and drags overall growth.
PAT momentum negative: -37.6% QoQ despite +92% YoY. Seasonality is cited, but QoQ deterioration is material and signal real softness.
License revenue and outcome/license mix are strategic but unproven. 3% of revenue; 60% target timeline tightened but still vague on execution.
Reorganization underway with new CCO and three-pillar structure adds near-term execution risk while providing long-term clarity.
No FY27 guidance given—unusual and signals management uncertainty on trajectory. Street will assume slower near-term growth until proven otherwise.
Risks ranked by holder concern
TMT structural headwind—bottoming unproven
HighDown 22% YoY this quarter, dragging overall growth from 37% ex-TMT to 20% headline. Tech capex/opex reallocation is durable; recovery timing is opaque. If TMT stays soft, headline growth will stay in the teens far below historical 19%+. This is the single largest drag on valuation re-rating.
Constant-currency growth stays at 9%, not rebounding to 19%
HighFX tailwind is temporary and reversible. If organic growth stabilizes at 9%, the narrative collapses from 'strong execution capturing AI' to 'mature-business growth in a competitive market.' Valuation re-rating from 35x to 20x forward earnings is possible.
License revenue execution delays or product-market fit failure
Medium3% of revenue now; 60% target is a 15x scaling over 'next few quarters.' Deal sizes are smaller than services; sales cycles likely longer. If Cogentiq stalls, the long-term margin/mix story evaporates and Fractal becomes a pure services play.
Execution reorganization friction in near term
MediumNew CCO, new structure, new vertical heads being hired. Moving faster is necessary but risky. Q2–Q3 can see deal delays, missed targets, or client churn as teams re-organize. Near-term earnings volatility is likely.
PAT momentum deteriorates further (QoQ -37.6% already)
MediumReported +92% YoY is eye-catching; QoQ -37.6% shows underlying weakness. If Q2 PAT declines YoY or stays negative QoQ, confidence in management's execution breaks and the stock re-rates sharply lower.
Qure.ai and Fractal Alpha losses dilute net income
LowQure.ai loss ₹23 Cr, Fractal Alpha loss ₹14 Cr. High-growth associates, but losses are material to consolidated PAT. Dependent on Qure.ai revenue conversion and Asper ARR lag closing in H2. Temporary, but adds noise and dilutes reported earnings.
The debate
What to watch next
1 · TMT sequential recovery signal
Management claims 'significant pipeline' and 'healthy sequential growth' ahead for Q2. This is the first real test. If TMT shows positive sequential growth—or even flattening of the YoY decline—it validates the bottoming narrative. If it declines further or stays negative sequentially, the TMT headwind is structural, not cyclical, and re-rating risk accelerates sharply.
2 · Constant-currency growth rebound to 12%+
Q1 was 9% cc. For Fractal to restore the 'growth' narrative, cc growth must rebound to 12%+ in Q2. This depends on TMT recovery, license revenue ramping, and existing-customer expansion. If it stays 9% or lower, the mature-business thesis gains traction and multiples stay compressed.
3 · License revenue and Cogentiq traction
Fractal will report Cogentiq revenue separately next quarter—the key metric. Early wins in underwriting, e-commerce, and supply chain need to show tangible revenue contribution, not just pipeline. If license revenue grows to 5%+ of total by Q3, the 60% target becomes credible. If it stays 3%, the strategy remains speculative and multiples stay under pressure.
The verdict
Fractal is not a broken story—it's a growth business in execution transition. The AI opportunity is real and structural; management is taking steps to capture it. But near-term delivery is soft: organic growth 9% vs. historical 19%, TMT unproven bottoming, license revenue unproven. The market's -8.67% day-1 reaction and 27% drawdown from ATH reflect justified skepticism. The single number to track from here is constant-currency growth. If it rebounds to 12%+ in Q2 as TMT recovers, the restructuring narrative holds and re-rating is justified. If it stays 9%, Fractal becomes a commodity IT services play with execution risk—a very different investment thesis entirely.
Fractal Q1: consolidated PAT +92% YoY to ₹72 Cr, revenue +20%; margins widen, TMT lags
PAT +91.8% YoY · revenue +20% · margins expanding
₹912.5 Cr
+20% YoY
₹72.3 Cr
+91.8% YoY
7.76%
₹4.31
Fractal Analytics' first full quarter as a listed company delivered consolidated revenue of ₹912.5 Cr (+20.0% YoY, +3.0% QoQ) and PAT of ₹72.3 Cr, up 91.8% YoY — or roughly +78% once a ₹6.9 Cr labour-code exceptional gain is stripped out and set against a year-ago base that carried no one-offs. Consolidated is the primary basis; standalone tells the same story (revenue ₹506 Cr +20%, PAT ₹75.3 Cr +85% YoY), so the two are not materially divergent.
Q1 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
The profit jump is genuine operating leverage, not a tax quirk: EBITDA rose ~39% YoY to ₹142.9 Cr and EBITDA margin expanded to 15.66% from 13.50%, while net margin widened to 7.9% from 5.0%. Growth was led by Healthcare & Life Sciences (+69% YoY), BFSI (+36%) and the largest vertical CPGR (+19%); management flagged TMT as the headline drag, noting the book grew 35% YoY excluding it. The one persistent weight is the Qure.ai associate, which cost ₹23.4 Cr this quarter (₹22.3 Cr a year ago) — management had guided on the Q4 call that this drag would cease, and it has not yet.
The stock went into the print at ₹786.75, down 17.3% over the past month of trading.
Management provides a positive outlook, suggesting historical revenue growth rates (around 19%) are a good indicator for the upcoming year. They anticipate continued margin expansion, driven by a strategic shift towards output, outcome, and license-based contracts, which are targeted to reach 60% of revenue in the next
— This quarter: met
The 38% sequential PAT decline looks alarming but is largely optical: Q4 FY26 PAT of ₹115.8 Cr was inflated by a large full-year deferred-tax credit, so YoY is the right lens here. Against management's own ~19% revenue-growth and margin-expansion guidance from the last call, the quarter delivers — revenue landed at ~20% and margins widened. Street coverage is thin given the February 2026 listing: Univest tracks a fair-value band around ₹895–1,010 versus a pre-result ₹886, with no clean quarterly consensus to beat or miss.
W1
Qure.ai associate drag ₹23.4 Cr this quarter — track whether it narrows toward the guided cessation.
W2
TMT recovery: headline held to +20% by TMT weakness while ex-TMT ran +35% — watch the gap close.
W3
Margin durability: EBITDA margin 15.66% (down from 20.33% QoQ) — verify guided expansion holds as license/outcome contracts scale toward the 60%-of-revenue target.
Digital-native PDF, clean read; source in ₹ Millions, converted ÷10 to ₹ Cr. Consolidated PBT bridge includes share of associate (Qure.ai) loss ₹23.4 Cr and a +₹6.9 Cr exceptional gain (statutory impact of new Labour Codes); PAT ₹72.3 Cr is total (owners of parent ₹74.2 Cr, NCI −₹1.9 Cr). Q1 FY26 (year-ago) figures Board-approved but not reviewed by auditor. EPS YoY not comparable (1:4 bonus Jul-2025 + CCPS conversion + IPO changed share count).